Vaishali Pharma Limited (NSE:VAISHALI)

Market Cap	974.55M -34.4%
Revenue (ttm)	1.09B +9.8%
Net Income	41.65M +409.5%
EPS	0.32 +433.3%
Shares Out	130.46M
PE Ratio	23.34
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	157,128
Open	7.47
Previous Close	7.47
Day's Range	7.24 - 7.49
52-Week Range	4.75 - 13.10
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Vaishali Pharma

Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti–malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 27
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: VAISHALI

Financial Performance

In fiscal year 2026, Vaishali Pharma's revenue was 1.09 billion, an increase of 9.84% compared to the previous year's 990.26 million. Earnings were 41.65 million, an increase of 409.52%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 30, 2026

Data Sources Report a data error